Connect with us


Hot Penny Stocks to Watch as the First Week of Trading Ends

Check these three penny stocks out for your watchlist right now
The post Hot Penny Stocks to Watch as the First Week of Trading Ends appeared first on Penny Stocks to Buy, Picks, News and Information |



3 Hot Penny Stocks to Add to Your Watchlist Today 

With another trading day here for penny stocks and blue chips, there is plenty for investors to keep track of. Right now, we’re seeing stock futures point to a lower open as a disappointing labor report ends the highly volatile week. 

However, despite the less than stellar news regarding jobs available, the unemployment rate hit a pandemic low of around 3.9%. So, while many investors expect January to remain highly volatile for penny stocks, we could see bullish action begin to move in once again. A lot depends on what happens with Covid and the Omicron variant in the next few weeks. 

[Read More] Best Penny Stocks to Buy Now? 3 Trump Stocks to Watch in January

While case numbers are increasing rapidly, the Omicron variant has time and time again been proven to be less severe for low-risk groups than previous variants. This means that combined with its high infection rate, we could potentially see the pandemic become endemic if all settles in the next few months. 

Now no one is waiting on the edge of their seats for that to occur, however, there is a sizable amount of hope for the future. Considering that there is so much to keep track of with penny stocks, investors need to stay on their toes. With all of that in mind, let’s take a look at three penny stocks to watch as the first week of trading comes to an end. 

3 Penny Stocks to Add to Your Watchlist Right Now 

  1. Phunware Inc. (NASDAQ: PHUN
  2. China Hgs Real Estate Inc. (NASDAQ: HGSH
  3. Marin Software Inc. (NASDAQ: MRIN

Phunware Inc. (NASDAQ: PHUN)

While PHUN stock had a disappointing run during premarket, it is also highly trending right now. Following its end-of-day spike on January 6th, shares are up by over 12% in the past five days. In the past six months however, PHUN stock has pushed up by a very sizable 147% to its current price of just over $3 per share. 

So, why has PHUN stock increased so much in that time? Well, the recent move from Phunware comes as the company made an exciting announcement yesterday. It stated that it has two new strategic supplier relationships as well as an optimized PC series to show at the Consumer Electronics Show or CES. 

“With these new strategic supplier relationships, we took the guesswork out of selecting the right personal computer systems for power users’ needs. Phunware launched these four newly optimized personal computers designed specifically for high-end gamers, traders, streamers, and cryptocurrency miners in conjunction with CES in Las Vegas.” 

The Vice President and General Manager of LYTE by Phunware, Caleb Borgstrom

This is great news for the company and should help to push it in the right direction for the near future. In addition to this, PHUN stock is often mentioned as a Reddit penny stock due to its highly trending nature. So, while PHUN can be quite volatile, it could be worth adding to your list of penny stocks to watch.

China Hgs Real Estate Inc. (NASDAQ: HGSH)

One of the largest gainers during premarket trading today is HGSH stock, pushing up by over 23% to just north of $2.21. While the company itself did not release any news, there are some speculative rumors surrounding it right now. 

[Read More] 4 Top Penny Stocks To Buy Right Now According To Insiders

Some traders believe that with Papa John’s new Chinese expansion plan, China Hgs could get a boost. Papa John’s released an announcement stating that it plans to increase its reach in China by over 1,350 stores. This is a major deal and as a real estate company, HGSH could be an obvious choice for investors to flock to. While there is no mention whatsoever that China Hgs will be working on this, with penny stocks, we often see rumors spark major gains (and losses). 

The latest company-specific news came out back in August when China Hgs released its first nine months fiscal 2021 financial report. Revenue during the third quarter alone came into around $31.8 million. This was a major increase of over 944% over its $3 million in the same quarter of 2020. With net income coming in at $3.6 million compared to $2.6 million in Q3 2020, it is clear that HGSH was and could be growing right now. With all of that in mind, does HGSH stock deserve a spot on your penny stocks watchlist this month?


Marin Software Inc. (NASDAQ: MRIN) 

Another major premarket gainer today is MRIN stock, shooting up by over 25%. The main reason for this gain comes as the company announced its integration with Amazon Ads platform known as DSP or demand-side platform. 

The integration will offer Marin the ability to give its customers management, measurement, and optimization of their Amazon ads. This pertains to its MarinOne Platform which has become extremely popular in the field of marketing and advertising. Since 2007, Marin has managed over $40 billion in ad spend online. This includes those utilizing paid search, retail media, and much more. 

“Amazon is great for the success of Retail brands. By integrating with Amazon DSP, we can now offer our customers access to a broad new set of formats, placements, and audiences to further their Amazon programs and deliver more return on investment within their eCommerce ad spend.” 

The CEO of Marin Software, Chris Lien

This is great news for the company and should continue to play out into the future. Whether this makes MRIN stock worth buying, however, is up to you. 

Penny_Stocks_to_Watch_Marin Software (MRIN Stock Chart)

Are Penny Stocks Worth Buying Right Now?

The short answer to this question is that it completely depends on you and your trading method. While penny stocks are highly volatile, they also present plenty of opportunity to profit. And although making money with penny stocks can be challenging, with the right information on hand, it can be much easier than previously imagined. 

[Read More] Energy Penny Stocks Are Climbing Today, Here’s 3 to Watch And Why

So, as we continue to barrel into 2022, there is plenty for investors to take note of. And, having a trading strategy that is malleable to what’s going on, continues to be the best way to minimize losses. Considering all of this, do you think that penny stocks are worth buying right now?

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!

The post Hot Penny Stocks to Watch as the First Week of Trading Ends appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


Pfizer Inc (NYSE: PFE) To Acquire Global Blood Therapeutics For $5 Billion

According to sources familiar with the matter, the Wall Street Journal reported that Pfizer Inc (NYSE: PFE) was in advanced discussions to acquire pharmaceutical…



According to sources familiar with the matter, the Wall Street Journal reported that Pfizer Inc (NYSE: PFE) was in advanced discussions to acquire pharmaceutical company Global Blood Therapeutics (NASDAQ: GBT) for $5 billion.

Pfizer, too, acquired Global Blood Therapeutics 

Pfizer wants to close a deal soon, but there are still other interested parties, according to the article.

Global Blood Therapeutics, which manufactures Oxbryta, the blood disorder medication, saw its shares jump 44%  on Friday afternoon to a two-year high. As of Thursday’s closing, the company’s market cap was $3.12 billion.

A spokesman for Global Blood stated the company does not “comment on market rumors or speculation,” while Pfizer declined to respond on the matter.

With plenty of cash left over after selling its COVID-19 vaccine, New York-based Pfizer is searching for deals that may generate billions of dollars annual sales by 2030.

Its $11.6 billion acquisition of migraine medication manufacturer Biohaven Pharmaceutical Holding (NASDAQ: BHVN) in May was the most recent in a series of purchases that also included Trillium Therapeutics and Arena Pharmaceuticals in recent years.

Oxbryta received approval last year for sickle cell disease management 

In 2019, the US government approved Global Blood’s Oxbryta to manage sickle cell disease in individuals aged 12 and over. The oral medication was approved in December 2021 to treat the illness in younger children. The drug’s sales increased by almost 50% to $194.7 million in 2021.

After a gloomy start to the calendar year, when a lack of significant purchases and clinical-stage treatment failures lowered investor morale and restricted funding, the biotech dealmaking pace has recently picked up again.

Also, Amgen Inc (NASDAQ: AMGN) also decided to purchase ChemoCentryx Inc on Thursday for $3.7 billion to obtain access to a possible breakthrough medication for inflammatory illnesses. AstraZeneca’s $39 billion acquisition of Alexion Pharmaceuticals in 2020 has put the realm of immune diseases in the limelight. The deal, which was announced before trading opened, will also give the corporation control of at least two investigational immune disorders medicines.

Please make sure to read and completely understand our disclaimer at While reading this article one must assume that we may be compensated for posting this content on our website.

The post Pfizer Inc (NYSE: PFE) To Acquire Global Blood Therapeutics For $5 Billion appeared first on Wall Street PR.

Read More

Continue Reading


AEMD: Positive Results in a Range of Conditions, Including COVID-19 & Monkey Pox

By M. Marin
Expanding the Potential Indications for Hemopurifier Treatment
Aethlon Medical’s (NASDAQ: AEMD)…



By M. Marin



Expanding the Potential Indications for Hemopurifier Treatment

Aethlon Medical's (NASDAQ: AEMD) clinical trials are moving forward and expanding, as AEMD continues to demonstrate the effectiveness of its lead product, the Aethlon Hemopurifier®, in a broad range of viruses and conditions in single patient emergency use cases and in in vitro analysis, including COVID-19 and various variants and Monkey Pox, among others. The Aethlon Hemopurifier® is being studied in a severe COVID-19 clinical trial under the company's open IDE (Investigational Device Exemption) for life-threatening viral infections.

The safety and feasibility of the Hemopurifier is being evaluated in an Early Feasibility Study (EFS) that will enroll up to 40 COVID-19 ICU patients. The first patient was enrolled in this study in June 2022 and has completed the Hemopurifier treatment. AEMD has nine fully activated hospitals that are actively screening patients for the trial.

In addition to this study, the Hemopurifier has demonstrated positive results in two severely ill patients under individual emergency use and in in vitro analysis. The Hemopurifier has produced positive results in binding seven variants of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus in vitro, as discussed in an article1  that AEMD's CEO Dr. Charles J. Fisher Jr. and the company's Chief Medical Officer Dr. Steven LaRosa contributed to.

The company is also conducting a study of the impact of the ...

Full story available on

Read More

Continue Reading


Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Authored by Mike Shedlock via,

The Eurodollar curve…



Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Authored by Mike Shedlock via,

The Eurodollar curve implies four quarter-point cuts are on the way starting in 2023. The Fed believes otherwise. Let's discuss stock market implications.

Data from CME and Fed via Wall Street Journal.

Eurodollar Curve

The eurodollar curve has nothing to do with euros or dollars. Rather it is an interest rate curve and one of the world's most widely traded futures.

After peaking at about 3.9% this year, eurodollar betters believe the Fed will then cut rates all the way down to 2.8%. 

Five Not-Quite-Impossible Things the Market Believes

Wall Street Journal Contributor James Macintosh discussed the above chart in Five Not-Quite-Impossible Things the Market Believes

  1. Inflation is transitory. 

  2. The Fed realizes this in time.

  3. The jobs market cools enough to slow wage rises. 

  4. But not so much it means falling household spending.

  5. So consumer spending rises in real terms. 

In reference to the led chart, Macintosh says "The first assumption is the hardest to believe."

I disagree. The hardest thing to believe is the overall goldilocks scenario and that the current rally makes any sense at all. 

Inflation may easily come down if the Fed tightens too much too fast causing a severe recession. What would that do to corporate profits? 

But assume otherwise, that inflation does not come down more. What would that do to corporate profits? 

While any of the first three points may easily be correct, the combination of all five being correct and that stocks will rise in a goldilocks scenario is what I find hard to believe.

Is the Market Forward Looking?

Goldilocks proponents will tell you that the market is forward looking. 

The market isn't forward looking and never was. It is a coincident indicator of current sentiment, wildly wrong at major turns.

If the market was forward looking, what precisely was it looking forward to at the November 2007 peak with recession starting the next month? 

What was it looking forward to at the 1929 peak, the 1933 bottom, the 2009 bottom or any other top or bottom?

The Fed Will Hike Until It Breaks Something

I believe the eurodollar curve is more likely to be correct than the Fed. When has the Fed gotten much of anything correct?

The eurodollar view has two ways to win. The first is the Fed actually does tame inflation to the degree that it wants.

That's possible in a severe enough recession. And the global picture is easily weak enough for that to happen.

The second way the eurodollar curve might be correct is if the Fed breaks the credit market. 

The Fed would immediately reverse course, regardless of inflation, should that happen. 

Neither a credit event nor strong recession would be good for the stock market.

The least likely thing is that the Fed achieves a goldilocks soft landing. Yet, assume that happens. 

Macintosh says, and I agree, "The bull case that stocks and corporate bonds are pricing requires the combination of low joblessness and wage rises to allow spending to rise faster than inflation even after pandemic savings run out. But not so much faster that it hits capacity constraints and accelerates inflation."

The problem with goldilocks is stocks are priced so much beyond perfection that they may decline anyway. 

Globally Speaking 

  1. China Does Surprise Rate Cut to Help Its Economy, But It Won't Work

  2. German Costs to Ship by Barge are up Twenty Times and May Soon Be Impossible

  3. UK Average Electricity Cost Will Soar to $5,370 Per Year By 2023

  4. US Industries Are Buckling Under Pressure of Surging Electricity Costs

Good luck with goldilocks, especially with the Fed still hiking. 

*  *  *

Please Subscribe to MishTalk Email Alerts.

Tyler Durden Wed, 08/17/2022 - 09:45

Read More

Continue Reading